II. Indications
- Psychosis
- Delirium
- Schizophrenia
- Tic Disorders (including Tourette's Syndrome)
- Acute Mania
III. Contraindications
- Pregnancy and Lactation
- Phencyclidine (PCP) Overdose
- Anticholinergic Syndromes
- Alcohol or Benzodiazepine Withdrawal
- Hepatic Insufficiency
- Neuroleptic Malignant Syndrome
IV. Class
- First Generation Antipsychotic
V. Dosing: Haloperidol
- Dose
- Adult: 5-10 mg PO, IM, or IV
- Peds: 0.5-1 mg PO, IM or IV
- Adolescent: 1-5 mg PO, IM or IV
- Elderly: 0.5-2 mg PO, IM or IV
- Intervals: Scheduled and repeated dosing intervals
- May repeat every 30-60 minutes
- Maximum: 300 mg/24 hours (avoid cummulative dose over 100 mg in 24 hours)
- May dose regularly every 6-8 hours
- Typical effective dose: 5 mg PO, IV, or IM tid (lower doses in the elderly)
- Total dose >3 mg/day is associated with Extrapyramidal Side Effects
VI. Dosing: Haloperidol decanoate (depot form)
- Haloperidol decanoate 100 mg IM every 4 weeks
- Cost effective (may be as low as $19 generic)
VII. Precautions
- Intravenous doses have a much shorter duration of action than other routes
- Antipsychotics are associated with increased mortality in the elderly
VIII. Adverse effects
- Serious
- See Extrapyramidal Side Effects (EPSE)
- Neuroleptic Malignant Syndrome
- Hypotension
- Dystonia
- Seizures
- Prolonged QT interval
- Risk of Torsades de Pointes
- Dose related effect with higher risk at higher doses
- Common
- Insomnia
- Restlessness
- Anxiety
- Sedation
- Headache
- Weight gain
- Hyperprolactinemia
- Blood dyscrasia
IX. Monitoring
-
Serum Prolactin
- Obtain if indicated
-
Complete Blood Count (indicated if history of Leukopenia)
- Baseline
- Monthly in first 3 months of therapy
Images: Related links to external sites (from Bing)
Related Studies
| Haloperidol (on 6/18/2017 at Walmart.com) | ||
| Haloperidol 0.5mg | #30 tablets for $4.00 | $0.13 each |
| Haloperidol 0.5mg | #90 tablets for $10.00 | $0.11 each |
| Haloperidol 1mg | #30 tablets for $4.00 | $0.13 each |
| Haloperidol 1mg | #90 tablets for $10.00 | $0.11 each |
| Haloperidol 2mg | #30 tablets for $4.00 | $0.13 each |
| Haloperidol 2mg | #90 tablets for $10.00 | $0.11 each |
| Haloperidol 5mg | #30 tablets for $4.00 | $0.13 each |
| Haloperidol 5mg | #90 tablets for $10.00 | $0.11 each |
| haloperidol (on 5/17/2017 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| HALOPERIDOL 0.5 MG TABLET | Generic | $0.22 each |
| HALOPERIDOL 1 MG TABLET | Generic | $0.27 each |
| HALOPERIDOL 10 MG TABLET | Generic | $0.57 each |
| HALOPERIDOL 2 MG TABLET | Generic | $0.35 each |
| HALOPERIDOL 20 MG TABLET | Generic | $1.38 each |
| HALOPERIDOL 5 MG TABLET | Generic | $0.45 each |
| HALOPERIDOL LAC 2 MG/ML CONC | Generic | $0.06 per ml |
| HALOPERIDOL LAC 5 MG/ML VIAL | Generic | $0.79 per ml |
Ontology: Haloperidol (C0018546)
| Definition (MSH) | A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) |
| Definition (NCI_NCI-GLOSS) | A drug used to treat certain mental and neurological disorders. It is also being studied in the treatment of nausea and vomiting caused by some cancer treatments. It is a type of antiemetic and a type of antipsychotic. |
| Definition (NCI) | A phenylbutylpiperadine derivative with antipsychotic, neuroleptic, and antiemetic activities. Haloperidol competitively blocks postsynaptic dopamine (D2) receptors in the mesolimbic system of the brain, thereby eliminating dopamine neurotransmission and leading to antidelusionary and antihallucinagenic effects. Antagonistic activity mediated through D2 dopamine receptors in the chemoreceptive trigger zone (CTZ) accounts for its antiemetic activity. |
| Definition (CSP) | USP lists as an antipsychotic and as an "antidyskinetic" used in Tourette syndrome. |
| Definition (PDQ) | A phenylbutylpiperadine derivative with antipsychotic, neuroleptic and antiemetic effects. Haloperidol competitively blocks postsynaptic dopamine (D2) receptors in the mesolimbic system of the brain, thereby eliminating dopamine neurotransmission and leading to antidelusionary and antihallucinagenic effects. The antagonistic activity mediated through D2 dopamine receptors in the chemoreceptive trigger zone (CTZ) accounts for its antiemetic activity. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39474&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39474&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C537" NCI Thesaurus) |
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | D006220 |
| SnomedCT | 321415008, 323259009, 10756001, 386837002 |
| LNC | LP16158-5, MTHU005005 |
| English | Haloperidol, 1-Butanone, 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-, Haloperidol [antipsychotic], Haloperidol [tics, chorea], Haloperidol [tics, chorea] [see D47..], 4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone, HALOPERIDOL, haloperidol (medication), Haloperidol [Chemical/Ingredient], Haloperidol [tics, chorea] [see D47..] (product), Haloperidol [antipsychotic] (product), haloperidol, Haloperidol (product), Haloperidol (substance), Haloperidol [antipsychotic] (substance), Haloperidol [tics, chorea] [see D47..] (substance) |
| Swedish | Haloperidol |
| Czech | haloperidol |
| Finnish | Haloperidoli |
| Russian | GALOPERIDOL, ГАЛОПЕРИДОЛ |
| Japanese | ハロペリドール |
| Croatian | HALOPERIDOL |
| Polish | Haloperidol |
| Spanish | haloperidol [tics, corea] [véase D47..] (producto), haloperidol [antipsicótico], haloperidol [tics, corea] [véase D47..], haloperidol [antipsicótico] (producto), haloperidol (producto), haloperidol (sustancia), haloperidol, Haloperidol |
| French | Halopéridol |
| German | Haloperidol |
| Italian | Aloperidolo |
| Portuguese | Haloperidol |
Ontology: haloperidol decanoate (C0062103)
| Definition (NCI) | The decanoate ester of haloperidol, a phenylbutylpiperadine derivative with antipsychotic, neuroleptic and antiemetic effects. Haloperidol competitively blocks postsynaptic dopamine (D2) receptors in the mesolimbic system of the brain leading to anti-delusionary and anti-hallucinogenic effects. The antagonistic activity mediated through D2 dopamine receptors in the chemoreceptive trigger zone (CTZ) account for its antiemetic activity. |
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | C033563 |
| SnomedCT | 412196004, 321699007 |
| English | haloperidol decanoate, Haloperidol Decanoate, Haloperidol deconoate, haloperidol decanoate (discontinued) (medication), haloperidol decanoate (discontinued), haloperidol decanoate [Chemical/Ingredient], HALOPERIDOL DECANOATE, Haloperidol decanoate, Haloperidol decanoate (product), Haloperidol decanoate (substance), Haloperidol deconoate (substance) |
| Spanish | decanoato de haloperidol (producto), decanoato de haloperidol, decanoato de haloperidol (sustancia) |
Ontology: Haldol (C0591585)
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | D006220 |
| English | Haldol, haldol |
Ontology: Haloperidol lactate (C0720809)
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| SnomedCT | 412197008 |
| English | haloperidol lactate, haloperidol lactate (medication), Haloperidol lactate, HALOPERIDOL LACTATE, Haloperidol Lactate, Haloperidol lactate (substance) |
| Spanish | lactato de haloperidol (sustancia), lactato de haloperidol |
